HTFLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Heartflow, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$51.02+2.73 (+5.65%)
Close on Oct 19, 2026
- Market cap
- $4.41B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
86.0%
75M of 87M shares
Institutional holders
193
51 new, 24 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
1 buys · 36 sales
Net sold $137.02M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wellington Management Group LLP | 9,232,829 | 10.70% | 13G (passive) amendment | Jul 31, 2026 |
| BCLS Fund III Investments, LP | 8,448,158 | 9.80% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Management Company LLP | 7,864,226 | 8.90% | 13G (passive) amendment | Jun 30, 2026 |
| Hayfin Management Holdings Limited | 5,283,264 | 6.20% | 13G (passive) | Sep 30, 2025 |
| BlackRock, Inc. | 4,934,928 | 5.70% | 13G (passive) | Jun 30, 2026 |
| FMR LLC | 4,730,234 | 5.70% | 13G (passive) | Sep 30, 2025 |
| Wellington Group Holdings LLP | 11,921,247 | 14.00% | 13G (passive) amendment | Feb 27, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HTFL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,448,158 | 9.72% | $247.87M | −2,000,000 | 14.74% |
| Wellington Management Group Llp | 7,864,226 | 9.04% | $230.74M | −4,118,057 | 0.04% |
| BlackRock, Inc. | 5,197,747 | 5.98% | $152.50M | +3,735,163 | 0.00% |
| FMR LLC | 4,820,944 | 5.54% | $141.45M | −576,858 | 0.01% |
| Vanguard Portfolio Management LLC | 3,584,428 | 4.12% | $105.17M | +1,538,490 | 0.00% |
| Bamco Inc /Ny/ | 3,225,133 | 3.71% | $94.63M | −602,398 | 0.14% |
| Vanguard Capital Management LLC | 2,753,206 | 3.17% | $80.78M | +859,711 | 0.00% |
| Jupiter Topco LLC | 2,419,336 | 2.78% | $70.98M | New | 0.03% |
| Invesco Ltd. | 2,298,718 | 2.64% | $67.44M | +385,628 | 0.01% |
| Alliancebernstein L.P. | 1,924,268 | 2.21% | $46.82M | +699,942 | 0.02% |
| Point72 Asset Management, L.P. | 1,721,279 | 1.98% | $50.50M | +1,182,928 | 0.06% |
| Summit Partners Public Asset Management, LLC | 1,694,651 | 1.95% | $49.72M | +802,558 | 0.87% |
| State Street Corp | 1,465,895 | 1.69% | $43.27M | +1,015,345 | 0.00% |
| UBS Asset Management Americas Inc | 1,465,650 | 1.69% | $43.00M | +50,822 | 0.01% |
| Geode Capital Management, LLC | 1,360,391 | 1.56% | $39.92M | +818,732 | 0.00% |
| Nuveen, LLC | 1,353,168 | 1.56% | $39.70M | +1,329,929 | 0.01% |
| Morgan Stanley | 1,054,889 | 1.21% | $30.95M | +202,957 | 0.00% |
| UBS Group AG | 975,510 | 1.12% | $28.62M | +546,426 | 0.00% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 931,160 | 1.07% | $27.32M | New | 0.03% |
| Millennium Management LLC | 922,893 | 1.06% | $27.08M | −170,524 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 193 | 75M | 86.0% | 51 / 91 | 37 / 24 | 24M | 12M |
| Q1 2026 | 169 | 65M | 74.8% | 75 / 50 | 26 / 15 | 24M | 10M |
| Q4 2025 | 112 | 52M | 60.2% | 49 / 37 | 13 / 24 | 12M | 4M |
| Q3 2025 | 89 | 45M | 51.5% | 89 / 0 | 0 / 0 | 45M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of HTFL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 5,795,579 | 6.67% | $146.22M | 0.38% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,467,177 | 2.84% | $72.39M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,077,580 | 2.39% | $60.96M | 0.07% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,781,440 | 2.05% | $52.27M | 0.03% | Jun 30, 2026 |
| Baron Discovery Fund | 1,604,894 | 1.85% | $47.09M | 2.57% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 1,127,593 | 1.30% | $33.08M | 0.05% | Jun 30, 2026 |
| Invesco Discovery Fund | 1,116,228 | 1.28% | $34.58M | 0.44% | May 31, 2026 |
| Select Health Care Portfolio | 1,000,000 | 1.15% | $30.98M | 0.54% | May 31, 2026 |
| Select Medical Technology and Devices Portfolio | 950,000 | 1.09% | $29.43M | 0.99% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 879,047 | 1.01% | $22.18M | 0.07% | Jul 31, 2026 |
| AB Small Cap Growth Portfolio | 830,401 | 0.95% | $24.36M | 0.78% | Jun 30, 2026 |
| Janus Henderson Venture Fund | 781,479 | 0.90% | $22.93M | 0.63% | Jun 30, 2026 |
| Franklin Dynatech Fund | 750,000 | 0.86% | $22.01M | 0.07% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 742,105 | 0.85% | $21.77M | 0.14% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 618,055 | 0.71% | $18.13M | 0.31% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John C.M. Farquhar | Chief Executive Officer, Director | 321,914 | 0.37% | Sep 14, 2026 |
| Campbell Rogers | Chief Medical Officer | 244,328 | 0.28% | Sep 21, 2026 |
| Vikram Verghese | Chief Financial Officer | 155,183 | 0.18% | Sep 18, 2026 |
| Marie L. Jones | Chief Accounting Officer | 32,176 | 0.04% | Aug 10, 2026 |
| Jeffrey C. Lightcap | Director | 6,991,237 | 8.04% | Jul 28, 2026 |
| Timothy C. Barabe | Director | 188,231 | 0.22% | Jul 24, 2026 |
| William C. Weldon | Director | 243,931 | 0.28% | Jul 10, 2026 |
| Casey M. Tansey | Director | 3,187,509 | 3.67% | Jun 18, 2026 |
| Wayne Joseph Riley | Director | – | – | Jun 18, 2026 |
| Julie A. Cullivan | Director | 27,291 | 0.03% | Jun 18, 2026 |
| Partners Management LP HealthCor | Director | 0 | – | Mar 26, 2026 |
| Nicholas Downing | Director | – | – | Aug 7, 2025 |
| Bain Capital Life Sciences Fund III, L.P. | 10% owner | 12,448,158 | 14.32% | Apr 30, 2026 |
| Bain Capital Life Sciences III General Partner, LLC | 10% owner | 8,448,158 | 9.72% | Apr 30, 2026 |
| BCLS Fund III Investments, LP | 10% owner | – | – | Apr 30, 2026 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | 10,448,158 | 12.02% | Apr 30, 2026 |
| BCLS Fund III Investments GP, LLC | 10% owner | – | – | Apr 30, 2026 |
| HealthCor Partners Fund II, L.P. | 10% owner | – | – | Aug 22, 2025 |
| Partners Fund LP HealthCor | 10% owner | – | – | Aug 22, 2025 |
| Partners LP HealthCor | 10% owner | – | – | Aug 22, 2025 |
| HealthCor Partners GP, LLC | 10% owner | 6,697,556 | 7.70% | Aug 22, 2025 |
| Hcpciv 1, Llc | 10% owner | – | – | Aug 22, 2025 |
| HealthCor Partners II, L.P. | 10% owner | – | – | Aug 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Campbell Rogers Chief Medical Officer | Sep 18, 2026 | Option exercise | +12,329 | $8.33 | $102.70K | 98,788 |
| Campbell Rogers Chief Medical Officer | Sep 18, 2026 | Option exercise | +850 | $2.22 | $1.89K | 99,638 |
| Campbell Rogers Chief Medical Officer | Sep 18, 2026 | Sale(10b5-1 plan) | −19,682 | $50.15 | $987.05K | 79,956 |
| Vikram Verghese Chief Financial Officer | Sep 18, 2026 | Sale(10b5-1 plan) | −16,766 | $50.75 | $850.87K | 155,183 |
| Vikram Verghese Chief Financial Officer | Sep 17, 2026 | Sale(10b5-1 plan) | −7,579 | $50.11 | $379.78K | 171,949 |
| Vikram Verghese Chief Financial Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −668 | $50.01 | $33.41K | 179,528 |
| Vikram Verghese Chief Financial Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −4,593 | $50.24 | $230.75K | 180,196 |
| Vikram Verghese Chief Financial Officer | Sep 11, 2026 | Sale(10b5-1 plan) | −29,714 | $50.06 | $1.49M | 184,789 |
| John C.M. Farquhar Chief Executive Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −3,890 | $50.00 | $194.50K | 321,914 |
| John C.M. Farquhar Chief Executive Officer, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −35,010 | $46.42 | $1.63M | 325,804 |
| Vikram Verghese Chief Financial Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −6,640 | $50.03 | $332.20K | 214,503 |
| Vikram Verghese Chief Financial Officer | Sep 3, 2026 | Sale(10b5-1 plan) | −27,540 | $49.69 | $1.37M | 221,143 |
| Vikram Verghese Chief Financial Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −5,876 | $50.60 | $297.33K | 248,683 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 21, 2026 | Sale(10b5-1 plan) | −27,230 | $50.00 | $1.36M | 360,814 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −32,676 | $45.00 | $1.47M | 388,044 |
| Campbell Rogers Chief Medical Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −9,219 | $41.23 | $380.10K | 86,459 |
| Campbell Rogers Chief Medical Officer | Aug 17, 2026 | Option exercise | +9,219 | $19.00 | $175.16K | 95,678 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 14, 2026 | Sale(10b5-1 plan) | −15,560 | $39.06 | $607.77K | 420,720 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −22,562 | $28.31 | $638.73K | 436,280 |
| Vikram Verghese Chief Financial Officer | Aug 7, 2026 | Tax withholding | −473 | $28.82 | $13.63K | 254,559 |
| Campbell Rogers Chief Medical Officer | Aug 7, 2026 | Tax withholding | −637 | $28.82 | $18.36K | 86,459 |
| Marie L. Jones Chief Accounting Officer | Aug 7, 2026 | Tax withholding | −82 | $28.82 | $2.36K | 32,176 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 7, 2026 | Tax withholding | −1,904 | $28.82 | $54.87K | 458,842 |
| Vikram Verghese Chief Financial Officer | Aug 6, 2026 | Tax withholding | −1,537 | $27.19 | $41.79K | 255,032 |
| Campbell Rogers Chief Medical Officer | Aug 6, 2026 | Tax withholding | −1,635 | $27.19 | $44.46K | 87,096 |
| Marie L. Jones Chief Accounting Officer | Aug 6, 2026 | Tax withholding | −486 | $27.19 | $13.21K | 32,258 |
| John C.M. Farquhar Chief Executive Officer, Director | Aug 6, 2026 | Tax withholding | −5,847 | $27.19 | $158.98K | 460,746 |
| John C.M. Farquhar Chief Executive Officer, Director | Jul 30, 2026 | Option exercise | +18,694 | $2.22 | $41.50K | 456,856 |
| John C.M. Farquhar Chief Executive Officer, Director | Jul 30, 2026 | Option exercise | +2,789 | $8.33 | $23.23K | 438,162 |
| John C.M. Farquhar Chief Executive Officer, Director | Jul 30, 2026 | Option exercise | +9,737 | $9.58 | $93.28K | 466,593 |
| Vikram Verghese Chief Financial Officer | Jul 27, 2026 | Option exercise | +22,522 | $2.22 | $50.00K | 255,898 |
| Jeffrey C. Lightcap Director | Jul 24, 2026 | Option exercise | +47,420 | $19.00 | $900.98K | 293,681 |
| Timothy C. Barabe Director | Jul 22, 2026 | Option exercise | +3,710 | $19.00 | $70.49K | 188,231 |
| Vikram Verghese Chief Financial Officer | Jul 21, 2026 | Option exercise | +22,522 | $2.22 | $50.00K | 233,376 |
| Timothy C. Barabe Director | Jul 17, 2026 | Option exercise | +5,000 | $19.00 | $95.00K | 184,521 |
| Campbell Rogers Chief Medical Officer | Jul 15, 2026 | Option exercise | +9,219 | $19.00 | $175.16K | 97,950 |
| Campbell Rogers Chief Medical Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −9,219 | $25.72 | $237.11K | 88,731 |
| John C.M. Farquhar Chief Executive Officer, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −22,562 | $27.75 | $626.10K | 435,373 |
| William C. Weldon Director | Jul 8, 2026 | Option exercise | +17,123 | $8.33 | $142.63K | 243,931 |
| William C. Weldon Director | Jul 8, 2026 | Option exercise | +17,123 | $8.33 | $142.63K | 226,808 |
| William C. Weldon Director | Jul 8, 2026 | Option exercise | +17,123 | $8.33 | $142.63K | 209,685 |
| John C.M. Farquhar Chief Executive Officer, Director | Jun 24, 2026 | Sale(10b5-1 plan) | −38,900 | $35.00 | $1.36M | 457,935 |
| Campbell Rogers Chief Medical Officer | Jun 15, 2026 | Option exercise | +10,000 | $2.22 | $22.20K | 88,731 |
| John C.M. Farquhar Chief Executive Officer, Director | Jun 10, 2026 | Sale(10b5-1 plan) | −22,562 | $28.50 | $643.02K | 496,835 |
| Campbell Rogers Chief Medical Officer | May 18, 2026 | Sale(10b5-1 plan) | −9,219 | $28.34 | $261.27K | 78,731 |
| Campbell Rogers Chief Medical Officer | May 18, 2026 | Option exercise | +9,219 | $19.00 | $175.16K | 87,950 |
| John C.M. Farquhar Chief Executive Officer, Director | May 11, 2026 | Sale(10b5-1 plan) | −22,562 | $29.12 | $657.01K | 519,397 |
| John C.M. Farquhar Chief Executive Officer, Director | May 7, 2026 | Tax withholding | −1,904 | $29.98 | $57.08K | 541,959 |
| Vikram Verghese Chief Financial Officer | May 7, 2026 | Tax withholding | −473 | $29.98 | $14.18K | 210,854 |
| Campbell Rogers Chief Medical Officer | May 7, 2026 | Tax withholding | −637 | $29.98 | $19.10K | 78,731 |
| Marie L. Jones Chief Accounting Officer | May 7, 2026 | Tax withholding | −82 | $29.98 | $2.46K | 31,083 |
| John C.M. Farquhar Chief Executive Officer, Director | May 6, 2026 | Tax withholding | −5,300 | $30.29 | $160.54K | 543,863 |
| Vikram Verghese Chief Financial Officer | May 6, 2026 | Tax withholding | −1,536 | $30.29 | $46.53K | 211,327 |
| Campbell Rogers Chief Medical Officer | May 6, 2026 | Tax withholding | −1,634 | $30.29 | $49.49K | 79,368 |
| Marie L. Jones Chief Accounting Officer | May 6, 2026 | Tax withholding | −485 | $30.29 | $14.69K | 31,165 |
| Bain Capital Life Sciences III General Partner, LLC 10% owner | Apr 30, 2026 | Sale | −56,224 | $30.05 | $1.69M | 8,448,158 |
| Bain Capital Life Sciences III General Partner, LLC 10% owner | Apr 30, 2026 | Sale | −892,533 | $29.18 | $26.04M | 8,504,382 |
| Bain Capital Life Sciences III General Partner, LLC 10% owner | Apr 29, 2026 | Sale | −797,133 | $29.37 | $23.41M | 9,396,915 |
| Bain Capital Life Sciences III General Partner, LLC 10% owner | Apr 28, 2026 | Sale | −254,110 | $30.51 | $7.75M | 10,194,048 |
| John C.M. Farquhar Chief Executive Officer, Director | Apr 10, 2026 | Sale(10b5-1 plan) | −22,562 | $26.72 | $602.86K | 549,163 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| John C.M. Farquhar Officer, Director | Oct 13, 2026 | 38,900 | $1.93M | Oct 12, 2026 | Stock Option Exercise |
| Campbell Rogers Officer | Sep 18, 2026 | 19,682 | $987.05K | Sep 18, 2026 | Stock Option Exercise |
| Campbell Rogers Member of immediate family of any of the foregoing | Sep 18, 2026 | 5,653 | $283.50K | Sep 18, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 18, 2026 | 16,766 | $850.93K | Sep 18, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 17, 2026 | 7,579 | $379.82K | Sep 17, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 15, 2026 | 668 | $33.41K | Sep 15, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 14, 2026 | 4,593 | $230.74K | Sep 14, 2026 | Stock Option Exercise |
| John C.M. Farquhar Officer, Director | Sep 11, 2026 | 3,890 | $194.50K | Sep 11, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 11, 2026 | 29,714 | $1.49M | Sep 11, 2026 | Stock Option Exercise |
| John C.M. Farquhar Officer, Director | Sep 10, 2026 | 35,010 | $1.63M | Sep 10, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 8, 2026 | 6,640 | $332.21K | Sep 8, 2026 | Stock Option Exercise |
| Vikram Verghese Officer | Sep 3, 2026 | 27,540 | $1.37M | Sep 3, 2026 | Convertible Note |
| Vikram Verghese Officer | Sep 2, 2026 | 5,876 | $297.33K | Sep 2, 2026 | Restricted Stock Vesting |
| John C.M. Farquhar Officer, Director | Aug 21, 2026 | 27,230 | $1.36M | Aug 21, 2026 | Stock Option Exercise |
| John C.M. Farquhar Officer, Director | Aug 18, 2026 | 32,676 | $1.47M | Aug 18, 2026 | Stock Option Exercise |